Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study
Titel:
Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study
Auteur:
Tye-Din, Jason A Daveson, A James M Goel, Gautam Goldstein, Kaela E Hand, Holly L Neff, Kristin M Popp, Alina Taavela, Juha Maki, Markku Isola, Jorma Williams, Leslie J Truitt, Kenneth E Anderson, Robert P